Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
|
11B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
398B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Chengdu Olymvax Biopharmaceuticals Inc
Glance View
Chengdu Olymvax Biopharmaceuticals, Inc. engages in the research and development, manufacture, and sale of human-use vaccines. The company is headquartered in Chengdu, Sichuan and currently employs 440 full-time employees. The company went IPO on 2021-06-08. The firm's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The firm's main customers are center for disease control and prevention (CDC) customers.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Chengdu Olymvax Biopharmaceuticals Inc is 9.1%, which is above its 3-year median of 6%.
Over the last 3 years, Chengdu Olymvax Biopharmaceuticals Inc’s Net Margin has decreased from 12.3% to 9.1%. During this period, it reached a low of -1.3% on Jun 30, 2024 and a high of 12.3% on Aug 30, 2022.
